{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:22:37Z","timestamp":1723854157140},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,15]]},"DOI":"10.7759\/cureus.66974","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T06:13:37Z","timestamp":1723788817000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of Subcutaneous Panniculitis-Like T-cell Lymphoma After Immune Checkpoint Inhibitor Treatment"],"prefix":"10.7759","author":[{"given":"Tommy Y","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zartash","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia  M","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M","family":"Maley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani NN","year":"2022","unstructured":"Bennani NN, Kim HJ, Pederson LD, et al.. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022, 10:e004984. 10.1136\/jitc-2022-004984","journal-title":"J Immunother Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner L","year":"2018","unstructured":"Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018, 378:1947-8. 10.1056\/NEJMc1803181","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.12.033","article-title":"Nivolumab-associated cutaneous T-cell lymphoma","volume":"9","author":"Marks JA","year":"2021","unstructured":"Marks JA, Parker DC, Garrot LC, Lechowicz MJ. Nivolumab-associated cutaneous T-cell lymphoma. JAAD Case Rep. 2021, 9:39-41. 10.1016\/j.jdcr.2020.12.033","journal-title":"JAAD Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9405-22","article-title":"Development of acute adult T-cell leukemia following PD-1 blockade therapy for lung cancer","volume":"61","author":"Misawa K","year":"2022","unstructured":"Misawa K, Yasuda H, Matsuda H, et al.. Development of acute adult T-cell leukemia following PD-1 blockade therapy for lung cancer. Intern Med. 2022, 61:3421-4. 10.2169\/internalmedicine.9405-22","journal-title":"Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig T","year":"2017","unstructured":"Wartewig T, Kurgyis Z, Keppler S, et al.. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017, 552:121-5. 10.1038\/nature24649","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch DA","year":"2019","unstructured":"Rauch DA, Conlon KC, Janakiram M, et al.. Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood. 2019, 134:1406-14. 10.1182\/blood.2019002038","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber JS","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al.. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017, 35:785-92. 10.1200\/JCO.2015.66.1389","journal-title":"J Clin Oncol"},{"key":"ref8","article-title":"Subcutaneous panniculitis-like T-cell lymphoma","author":"Musick SR","year":"2024","unstructured":"Musick SR, Lynch DT. Subcutaneous panniculitis-like T-cell lymphoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/269896-development-of-subcutaneous-panniculitis-like-t-cell-lymphoma-after-immune-checkpoint-inhibitor-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T06:13:40Z","timestamp":1723788820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/269896-development-of-subcutaneous-panniculitis-like-t-cell-lymphoma-after-immune-checkpoint-inhibitor-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.66974","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}